Scarica l'app Stockscreener
3.88
0.26%
0.010
Dopo l'orario di chiusura:
3.89
0.01
+0.26%
Precedente Chiudi:
$3.87
Aprire:
$3.89
Volume 24 ore:
204.74K
Relative Volume:
0.37
Capitalizzazione di mercato:
$272.67M
Reddito:
$114.70K
Utile/perdita netta:
$-12.82M
Rapporto P/E:
-1.4513
EPS:
-2.6735
Flusso di cassa netto:
$-45.71M
1 W Prestazione:
+1.31%
1M Prestazione:
-4.67%
6M Prestazione:
+93.03%
1 anno Prestazione:
+210.40%
Intervallo 1D:
$3.83
$3.97
Intervallo di 1 settimana:
$3.76
$3.97
Portata 52W:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Nome
Sab Biotherapeutics Inc
Settore
Industria
Telefono
305-845-2813
Indirizzo
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.88 | 272.67M | 114.70K | -12.82M | -45.71M | -2.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-19 | Iniziato | Guggenheim | Buy |
| 2025-09-17 | Iniziato | Leerink Partners | Outperform |
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-10-09 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Rodman & Renshaw - MarketBeat
Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating By Investing.com - Investing.com India
Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating - Investing.com
SABSW SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - stocktitan.net
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 21.1% in March - MarketBeat
Published on: 2026-03-30 20:34:02 - baoquankhu1.vn
Published on: 2026-03-27 23:19:55 - baoquankhu1.vn
Institution Moves: Is SAB Biotherapeutics Inc stock a smart retirement pickIPO Watch & Pattern Based Trade Signal System - baoquankhu1.vn
SAB Biotherapeutics (SABS) CMO has common shares withheld for taxes - Stock Titan
SAB Biotherapeutics - Global Legal Chronicle
[SCHEDULE 13D/A] SAB Biotherapeutics, Inc. Amended Major Shareholder Report - Stock Titan
SAB Biotherapeutics Completes $85 Million Public Offering - Global Legal Chronicle
SAB Biotherapeutics closes $85 million public offering - The Pharma Letter
SAB Biotherapeutics (SABS) to Release Earnings on Friday - marketbeat.com
SAB Biotherapeutics announces public stock offering; shares down - MSN
SAB Biotherapeutics Closes $85 Million Securities Offering - marketscreener.com
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Weekly Voice
SAB Biotherapeutics (SABS) raises $69.7M net to advance SAB‑142 clinical program - Stock Titan
SAB Biotherapeutics Launches Major Equity Financing Offering - TipRanks
SAB Biotherapeutics (NASDAQ: SABS) to raise $85M for SAB-142 trials - Stock Titan
SAB Biotherapeutics Prices Underwritten Equity Offering; About $69.7 Million Net Proceeds Expected - TradingView
Stock Recap: Is SAB Biotherapeutics Inc being accumulated by smart money2026 Market Outlook & Low Volatility Stock Recommendations - baoquankhu1.vn
Guggenheim initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SAB Biotherapeutics prices $85M stock offering at $3.85/share By Investing.com - Investing.com South Africa
SAB Biotherapeutics prices $85M stock offering at $3.85/share - Investing.com
Sab Bio announces pricing of $85 million public offering of common stock at $3.85 per share - marketscreener.com
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
SAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 Million - quiverquant.com
SAB BIO plans $85M funding push for experimental type 1 diabetes treatment - Stock Titan
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Benzinga
SAB Biotherapeutics (SABS) to offer common stock and pre-funded warrants - Stock Titan
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Biotech SAB BIO plans stock sale to fund Type 1 diabetes trials - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update - MarketBeat
Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Cut to “Strong Sell” at Zacks Research - Defense World
SAB Biotherapeutics reports early C-peptide signals in phase 1 trial - Investing.com Nigeria
SAB Biotherapeutics (NASDAQ:SABS) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
SAB Biotherapeutics, Inc. Common Stock (SABS) Stock Price Today & Analysis - heygotrade.com
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
SAB Biotherapeutics (NASDAQ:SABS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Chardan Capital Raises SAB Biotherapeutics Price Target to $14 - National Today
Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00 - MarketBeat
H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution - Investing.com
RA Capital (SABS) reports 9.9% stake and adds two directors to board - Stock Titan
SAB Biotherapeutics (NASDAQ:SABS) Given New $7.00 Price Target at HC Wainwright - Defense World
SAB Biotherapeutics Announces Positive Phase 1 Results for SAB-142 Showing C-Peptide Preservation in Adult Type 1 Diabetes Patients - Minichart
SAB Biotherapeutics, Inc. 2024 Annual Report: Business Overview, Pipeline, and Strategic Outlook - Minichart
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes - National Today
Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):